Capital expenditure increased 109.2%
Capital expenditure changed +109.2% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed +109.2% from the comparable as-filed period. The change ranks at the 67th percentile of 6 prior comparable changes.
Free-cash-flow proxy changed +201.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Gross profit changed +10.6% from the comparable as-filed period.
Net income changed +126.1% from the comparable as-filed period.
Operating cash flow changed +207.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +179.2% from the comparable as-filed period.
Operating margin changed +572 basis points from the comparable as-filed period.
Stock-based compensation changed -17.6% from the comparable as-filed period.
Research & development changed -6.2% from the comparable as-filed period.
Revenue changed +9.8% from the comparable as-filed period.
Capex / revenue changed +16 basis points from the comparable as-filed period.
Cash & equivalents changed -0.0% from the comparable as-filed period.
Gross margin changed +47 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.